Status:
NOT_YET_RECRUITING
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
Lead Sponsor:
West China Hospital
Conditions:
High-grade Glioma
Eligibility:
All Genders
18-70 years
Brief Summary
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
Detailed Description
To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The ...
Eligibility Criteria
Inclusion
- Age ≥18 years old;
- High-grade glioma was confirmed by pathology after surgery;
- ECOG score 0-2 points;
- Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
- Baseline data available.
Exclusion
- The pathological diagnosis is not clear;
- No synchronous chemotherapy/adjuvant chemotherapy \< 6 cycles;
- There are other malignant tumors;
- Previously radiotherapy to the head;
- Interruption of radiotherapy for more than 5 days;
- Failure to collect baseline data.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06201351
Start Date
January 1 2024
End Date
September 30 2026
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041